Wolverine Legal Status, FDA 503A Category, and Compounding Access

Access is under active FDA review and may expand in 2026

The forward-leaning headline on Wolverine legal status first, because it is the live development: access to Wolverine's components is under active FDA review and may expand in 2026. The anchor for that statement is a scheduled fact — the FDA's Pharmacy Compounding Advisory Committee (PCAC) is set to meet on July 23-24, 2026 to discuss these peptides as candidates for the Section 503A Bulks List ^[17].

That is momentum, and it is real. It is also not a decision. A PCAC discussion is advisory — a step in evaluation, not a final FDA listing — and no outcome should be assumed, stated, or dated ^[18]. The present-tense status, below, is what is true today, and the rest of this page reads the FDA record straight. The 2026 meeting is what could change it.

The current fact: both components are FDA Category 2 (503A)

As of today, Wolverine's two components are research peptides that the FDA has placed in "Category 2" — bulk drug substances that may present significant safety risks — for the purposes of Section 503A pharmacy compounding ^[19]. That placement took effect with the FDA's September 29, 2023 update to its list of nominated bulk drug substances ^[19].

Under the U.S. Federal Food, Drug, and Cosmetic Act, drug compounding runs through two sections. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight ^[20]. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list ^[20].

Category 2 is the constraint that matters for access. Per FDA's interim policy, Category 2 substances were nominated with sufficient information to evaluate but were identified as raising significant safety risks; they are not covered by the enforcement-discretion policy that applies to Category 1, and FDA has stated it would consider taking action against a compounder using a Category 2 substance ^[21]. For BPC-157 and the TB-500 fragment, FDA's stated rationale includes potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization ^[19]. The practical consequence: compounding-pharmacy access to these peptides is currently restricted while that status stands. Neither is an FDA-approved drug, and the blend has no approved indication ^[19].

Both components are on the July 2026 PCAC agenda — no carve-out

Both of Wolverine's components are on the FDA PCAC July 23-24, 2026 agenda, listed as bulk drug substances being considered for inclusion on the 503A Bulks List ^[17]. There is no component carve-out: the agenda lists BPC-157 — the 15-amino-acid pentadecapeptide — as BPC-157 (free base) and BPC-157 acetate, and it lists the TB-500 fragment, which the FDA records as Thymosin beta-4, fragment (LKKTETQ), also known as TB-500, as TB-500 (free base) and TB-500 acetate ^[17][19]. The LKKTETQ motif is the actin-binding fragment of Thymosin Beta-4 that defines TB-500.

Both are currently Category 2, and both fall under this one scheduled review. Being discussed by PCAC is part of FDA's evaluation; it is not a final listing decision, and the outcome of the July 2026 meeting is unknown ^[18]. No reclassification has occurred, none is dated, and none is certain.

How legally compounded peptide access works

In general terms — this is information about the regulatory landscape, not medical or legal advice, and not an offer to supply anything — a legally compounded medication in the U.S. follows one pathway. A patient is evaluated by an appropriately licensed prescriber, in person or through a compliant telehealth encounter, who determines whether a compounded preparation is clinically appropriate ^[22]. If it is appropriate and lawful, the prescriber issues a valid, patient-specific prescription ^[22]. That prescription is then dispensed by a state-licensed 503A compounding pharmacy, or, for office and batch use, sourced from an FDA-registered 503B outsourcing facility ^[22].

Telehealth is a front-end channel for the prescriber-evaluation step, not a separate legal status: it does not expand which substances may be compounded and does not remove the need for a legitimate clinical evaluation and a valid prescription ^[23]. And one ingredient-eligibility caveat governs all of it — the compounder may use a requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules. Ingredients the FDA has flagged for significant safety risks, which currently includes both of Wolverine's components, are not eligible for routine 503A compounding while that status stands ^[22].

Legal status FAQ

Three direct questions on access and regulatory status, answered from the audited FDA record.